NBDC Research ID: hum0059.v1



Aims: Establishment of novel therapeutic strategy to overcome intractable cancer by molecular profiling of serous ovarian cancer

Methods: Exome analysis by using Illumina HiSeq 2000

Participants/Materials: 148 normal, primary tumor and relapse tumor tissues from 65 ovarian cancer


Data Set IDType of DataCriteriaRelease Date
JGAS00000000104 NGS (Exome) Controlled Access (Type I) 2018/04/06

*Release Note

* Data users need to apply the Form 2 (Application Form for Using NBDC Human Data) to reach the Controlled Access Data. Learn more





ovarian cancer: 65 cases (total: 148 samples)

   non-tumor tissues: 67 samples

   tumor tissues: 81 samples

Targets Exome
Target Loci for Capture Methods -
Platform Illumina [Hiseq 2000]
Library Source DNAs extracted from non-tumor, primary tumor, and relapse tumor tissues
Cell Lines -
Library Construction (kit name)

SureSelect Human All Exon V4 + lincRNA

SureSelect Human All Exon V5 + lincRNA

Fragmentation Methods Ultrasonic fragmentation (Covaris E220)
Spot Type Paired-end
Read Length (without Barcodes, Adaptors, Primers, and Linkers) 100 bp
Japanese Genotype-phenotype Archive Data set ID JGAD00000000109
Total Data Volume 3 TB (fastq)
Comments (Policies) NBDC policy & P-DIRECT policy



Principal Investigator: Kazuyoshi Kato

Affiliation: The Cancer Institute Hospital of JFCR

Project / Group Name: -

Funds / Grants (Research Project Number):

NameTitleProject Number
Project for Development of Innovative Research on Cancer Therapeutics (P-DIRECT) 15cm0106061h0005



TitleDOIData Set ID


USRES (Controlled-Access Data)

Principal Investigator: Affiliation: Data in Use (Data Set ID)Period of Data Use
Masaki Mandai Kyoto University Faculty of Medicene, department of Gynecology and Obstetrics JGAD00000000109 2018/10/04-2020/03/31